Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.

Expert review of pharmacoeconomics & outcomes research - 1 Mar 2026

Queiro Rubén, Braña Ignacio, Alvarez Paula, Loredo Marta, Pardo Estefanía, Burger Stefanie

Abstract excerpt

BACKGROUND: Psoriatic arthritis (PsA) requires long-term, phenotype-oriented management. This study compared the cost-utility of ixekizumab, tofacitinib, and golimumab using a real-world modeling approach. RESEARCH DESIGN AND METHODS: A 10-year Markov model was developed from the perspective of the Spanish National Health System, informed by three real-world PsA cohorts. Transition probabilities were derived from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Psoriatic

Share to Cost-Benefit Analysis

Share to Markov Chains

Share to Piperidines

Share to Pyrroles

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 41657049
DOI: 10.1080/14737167.2026.2629351

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.PMID 41657049Read ↗

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.Semantic proximity Read ↗

Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 StudiesSemantic proximity Read ↗

An Empirical Comparison of Statistical Methods for Estimating EQ-5D Health State Utilities in Rheumatoid Arthritis Clinical Trials for Economic ModellingSemantic proximity Read ↗

Evaluating the economic impact of eculizumab biosimilars in GermanySemantic proximity Read ↗

Comparative real-world retention rate and safety of Biosimilar IBI303 versus Humira in Ankylosing SpondylitisSemantic proximity Read ↗

A Game-Theoretic Perspective on Disease-Modifying Therapy Choice in Resource-Limited SettingsSemantic proximity Read ↗

Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups.Semantic proximity Read ↗

A Simulation-Based Discrete Choice Experiment Framework for Alzheimer’s Disease-Modifying Therapy Implementation: Methodology and Interactive Decision Support ToolSemantic proximity Read ↗

Predicting Cost-Effectiveness of Generic Versus Brand Dabigatran Using Pharmacometric Estimates among Patients with Atrial Fibrillation in the United StatesSemantic proximity Read ↗

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.Semantic proximity Read ↗

Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.